Abstract: In an embodiment a hub assembly includes an axle and a hub body, wherein the axle extends through the hub body in a longitudinal direction, wherein the hub body is rotatably supported relative to the axle via at least one rolling bearing, an end body fixed to or on the axle on a side of the rolling bearing facing away from the hub body, wherein a bearing section of the end body facing the rolling bearing as seen in the longitudinal direction is arranged on the inner ring of the rolling bearing and a compensating element arranged between the bearing section of the end body and the inner ring of the rolling bearing and/or between the bearing section of the hub body and the outer ring of the rolling bearing, wherein the compensating element has a variable extension when viewed in the longitudinal direction.

Abstract: The present invention provides compounds of formula (I) wherein X1, X2, R1 to R6 and A are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by bacteria.

Abstract: In an embodiment a hub for a bicycle running wheel includes a hub body and a freewheel body, wherein the hub body and the freewheel body are connected via a conical toothing arrangement.

Abstract: The disclosure refers to a hub for a bicycle running wheel, a bicycle drive system and a bicycle. In an embodiment a hub for a bicycle running wheel includes a hub body and a receiving area configured to receive a force transmission means, wherein the hub body and the receiving area are a single part or are firmly connected together.

Abstract: The present invention relates to a process for synthesizing large scale a compound of formula (I), or pharmacuetically acceptable salt thereof, which is useful as the key intermediate for the synthesis of compounds for prophylaxis and treatment of a disease associated with the deposition of ?-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.

Abstract: The present invention provides compounds of formula (I) wherein X1, X2, R1 to R6 and A are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by bacteria.

Abstract: Processes are described for the preparation of estrogen receptor modulating compound, (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid I: and salts thereof, and intermediates useful for the preparation of I.

Abstract: Processes are described for the preparation of estrogen receptor modulating compound, (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid I: and salts thereof, and intermediates useful for the preparation of I.

Abstract: The present invention is concerned with a novel process for the preparation of compounds of formula (I) wherein R1 and R2 are as defined in the description and claims. The compounds of formula (I) are pharmaceutically active substances.